arrow_back Back Filing freshness 10-Q FY 2028 SEC EDGAR

TuHURA Biosciences, Inc./NV

HURA
$2.12 ▲ +0.01 (+0.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
10 Visible periods
21 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, TuHURA Biosciences, Inc./NV shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $272.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share $-0.05
Trailing P/E 33.5x
Price / Book 138.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$8.05M
↓ -27.7%
FCF / Share Free cash flow per share
$-0.05
↑ +48.0%
Long-Term Debt Long-term obligations
$1.12K
↓ -96.0%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of -0.79x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 52 quarters